Nicotinamide Mononucleotide Derivatives for Treatment and Prevention of Sickle Cell Disease
Summary
The USPTO has published patent application US20260108550A1, filed June 13, 2025 (Application No. 19237807), covering nicotinamide mononucleotide (NMN) derivatives of Formula (I) for use in treating and/or preventing red blood cell disorders, specifically sickle cell disease. Inventors include Guillaume Bermond, Laurent Garçon, Matthias Canault, and Cecile Cros. The application is classified under CPC codes A61K 31/706, A61K 31/198, and A61P 7/06.
“The present invention relates to nicotinamide mononucleotide derivatives of Formula (I) for use in the treatment and/or prevention of a blood disorder, especially sickle cell disease.”
About this source
USPTO classification A61K covers pharmaceutical preparations: formulations, dosage forms, combination therapies, delivery systems, and the vehicles that carry active ingredients. Every newly published application in A61K lands in this feed, around 245 a month. Applications publish 18 months after filing, so this feed reveals what pharma formulators at major sponsors and generics were working on in the prior year and a half. Watch this if you compete in drug formulation, file freedom-to-operate analyses, scout competitive drug products before clinical readouts, or follow novel delivery platforms like nanoparticles, lipid carriers, and long-acting injectables.
What changed
The USPTO has published patent application US20260108550A1 disclosing NMN (nicotinamide mononucleotide) derivatives of Formula (I) for therapeutic use in treating and preventing red blood cell disorders, with specific focus on sickle cell disease. The application was filed on June 13, 2025, under Application No. 19237807, and names four inventors.
Pharmaceutical researchers and drug developers in the blood disorder space may wish to monitor this application's progression through the patent examination process. While a published patent application does not grant enforceable rights, it signals active development in the NMN-based therapeutic space for hemoglobinopathies and may inform prior art considerations for competing research programs.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND USE THEREOF IN THE TREATMENT AND PREVENTION OF A RED BLOOD CELL DISORDER
Application US20260108550A1 Kind: A1 Apr 23, 2026
Inventors
Guillaume BERMOND, Laurent GARÇON, Matthias CANAULT, Cecile CROS
Abstract
The present invention relates to nicotinamide mononucleotide derivatives of Formula (I) for use in the treatment and/or prevention of a blood disorder, especially sickle cell disease. The present invention further relates to pharmaceutical compositions comprising compounds of Formula (I) for use in the treatment and/or prevention of a red blood cell disorder, especially sickle cell disease.
CPC Classifications
A61K 31/706 A61K 31/198 A61P 7/06
Filing Date
2025-06-13
Application No.
19237807
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.